DPMI-omega is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-omega, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-omega can disrupte the p53-MDM2/MDMX complex. DPMI-omega can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-omega can augment the efficacy of immunotherapy by expanding CD3+/CD8+ cytotoxic T cells and suppressing CD4+/CD25+ regulatory T cells companied with anti-PD1 antibody. DPMI-omega can be used for research of melanoma[1].
Molecular Weight:
1693.34
Formula:
C82H114ClN17O20
Target:
MDM-2/p53
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
